LUZP1 and cholangiocarcinoma: As predicted, shallow and deep deletions (most probably homozygous deletions, according to cBioPortal) were associated to lower LUZP1 mRNA expression compared to diploid, gain or amplification events in cholangiocarcinoma (Figure 1B), breast cancer (Figure 1C) and prostate cancer (Figure 1D), indicating that genomic events are, at least in part, responsible for reduced LUZP1 expression associated to cancer.